MA26748A1 - Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation - Google Patents
Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisationInfo
- Publication number
- MA26748A1 MA26748A1 MA26033A MA26033A MA26748A1 MA 26748 A1 MA26748 A1 MA 26748A1 MA 26033 A MA26033 A MA 26033A MA 26033 A MA26033 A MA 26033A MA 26748 A1 MA26748 A1 MA 26748A1
- Authority
- MA
- Morocco
- Prior art keywords
- tetrahydrobenzo
- preparation
- medicaments containing
- azepine derivatives
- azepine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99115557 | 1999-08-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26748A1 true MA26748A1 (fr) | 2004-12-20 |
Family
ID=8238742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA26033A MA26748A1 (fr) | 1999-08-06 | 2000-08-01 | Derives de 1,2,4,5- tetrahydrobenzo[d]azepine, procede pour leur preparation, medicaments les contenant et leur utilisation |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US6218385B1 (fr) |
| JP (1) | JP3260350B2 (fr) |
| KR (1) | KR100390116B1 (fr) |
| CN (1) | CN1146455C (fr) |
| AR (1) | AR025035A1 (fr) |
| AT (1) | ATE254614T1 (fr) |
| AU (1) | AU774485B2 (fr) |
| BR (1) | BR0003375A (fr) |
| CA (1) | CA2314798A1 (fr) |
| CO (1) | CO5180625A1 (fr) |
| DE (1) | DE60006618T2 (fr) |
| ES (1) | ES2209728T3 (fr) |
| HR (1) | HRP20000520A2 (fr) |
| HU (1) | HUP0003112A3 (fr) |
| ID (1) | ID26743A (fr) |
| IL (1) | IL137688A0 (fr) |
| MA (1) | MA26748A1 (fr) |
| NO (1) | NO20003966L (fr) |
| NZ (1) | NZ506096A (fr) |
| PE (1) | PE20010467A1 (fr) |
| PL (1) | PL341890A1 (fr) |
| RU (1) | RU2240317C2 (fr) |
| SG (1) | SG93251A1 (fr) |
| TR (1) | TR200002298A3 (fr) |
| UY (1) | UY26276A1 (fr) |
| YU (1) | YU49700A (fr) |
| ZA (1) | ZA200003927B (fr) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE297734T1 (de) * | 2000-12-22 | 2005-07-15 | Hoffmann La Roche | Tetrahydro-(benzo- oder thieno-)azepin-pyrazin und triazinderivative als mglur 1 antagonisten |
| US6953787B2 (en) | 2002-04-12 | 2005-10-11 | Arena Pharmaceuticals, Inc. | 5HT2C receptor modulators |
| PT1572215E (pt) | 2002-12-20 | 2009-12-09 | Glaxo Group Ltd | Derivados de benzo[d]azepina para o tratamento de perturbações neurológicas |
| CN1805938B (zh) * | 2003-06-17 | 2010-06-16 | 艾尼纳制药公司 | 用于治疗5ht2c受体相关疾病的苯并氮杂卓衍生物 |
| US8367657B2 (en) * | 2003-06-17 | 2013-02-05 | Arena Pharmaceuticals, Inc. | Processes for preparing 3-benzazepines |
| WO2005042491A1 (fr) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Derives de benzazepine et methodes de prophylaxie ou traitement de maladies associees au recepteur 5ht2c |
| WO2005042490A1 (fr) * | 2003-10-22 | 2005-05-12 | Arena Pharmaceuticals, Inc. | Derives de benzazepine et methodes de prophylaxie ou de traitement de maladies associees au recepteur 5-ht2c |
| EP2149562A1 (fr) | 2004-12-21 | 2010-02-03 | Arena Pharmaceuticals, Inc. | Méthode pour préparer l'hemihydrate de l'hydrochlorure de (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| NZ589951A (en) * | 2004-12-23 | 2012-11-30 | Arena Pharm Inc | 5HT2C receptor modulator compositions and methods of use |
| EP2275096A3 (fr) | 2005-08-26 | 2011-07-13 | Braincells, Inc. | Neurogenese par modulation des recepteurs muscariniques |
| EP2258357A3 (fr) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenèse avec inhibiteur de l'acetylcholinestérase |
| WO2007047978A2 (fr) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation de la neurogenese par inhibition de la pde |
| EP2314289A1 (fr) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Modulation de la neurogenese dont la médiation est assurée par récepteur gaba |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| CA2646044A1 (fr) | 2006-04-03 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Procedes de preparation de 8-chloro-1-methyl-2,3,4,5-tetrahydro-1h-3-benzazepine et produits intermediaires associes |
| EP2021000A2 (fr) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenèse par modulation de l'angiotensine |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| EP1873527A1 (fr) * | 2006-06-30 | 2008-01-02 | Schwarz Pharma Ag | Procédé d'identification des modulateurs CRMP |
| WO2008030651A1 (fr) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinaisons contenant un dérivé de 4-acylaminopyridine |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| DK2083811T3 (en) | 2006-11-22 | 2017-01-30 | Clinical Res Ass Llc | PROCEDURES FOR TREATING DOWNS SYNDROME, FRAGILT X SYNDROME AND AUTISM |
| EP2099743B1 (fr) * | 2006-12-05 | 2014-08-27 | Arena Pharmaceuticals, Inc. | Procédés de préparation de (r)-8-chloro-1-méthyl-2,3,4,5-tétrahydro-1h-3-benzazépine et intermédiaires de celle-ci |
| TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| US8822727B2 (en) | 2008-03-04 | 2014-09-02 | Arena Pharmaceuticals, Inc. | Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine |
| US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2010148207A2 (fr) | 2009-06-18 | 2010-12-23 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
| US20130058915A1 (en) | 2010-03-02 | 2013-03-07 | Children's Medica Center Corporation | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
| WO2011150380A1 (fr) | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Méthodes de traitement du syndrome de l'x fragile, du syndrome de down, de l'autisme et des troubles associés |
| WO2011153206A1 (fr) | 2010-06-02 | 2011-12-08 | Arena Pharmaceuticals, Inc. | Procédés pour la préparation d'agonistes du récepteur 5-ht2c |
| US20120016021A1 (en) | 2010-07-15 | 2012-01-19 | Xenoport, Inc. | Methods of treating fragile x syndrome, down's syndrome, autism and related disorders |
| KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태 |
| EA201390335A1 (ru) | 2010-09-01 | 2013-09-30 | Арена Фармасьютикалз, Инк. | Введение лоркасерина индивидуумам с почечной недостаточностью |
| KR20130101524A (ko) | 2010-09-01 | 2013-09-13 | 아레나 파마슈티칼스, 인크. | 5-ht2c 아고니스트의 비-흡습성 염 |
| JP2013539470A (ja) | 2010-09-01 | 2013-10-24 | アリーナ ファーマシューティカルズ, インコーポレイテッド | ロルカセリンと光学活性な酸との塩 |
| RU2674670C1 (ru) | 2012-10-09 | 2018-12-12 | Арена Фармасьютикалз, Инк. | Способ коррекции массы тела |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4206210A (en) * | 1977-01-19 | 1980-06-03 | Smithkline Corporation | Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity |
| BR9107070A (pt) * | 1990-11-06 | 1994-05-31 | Pfizer | Processo para a preparação de derivados de quinazolina uteis para melhorar a atividade antitumoral. |
| US5241065A (en) * | 1992-02-25 | 1993-08-31 | Schering Corporation | 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity |
| AU678503B2 (en) * | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
-
2000
- 2000-07-27 ES ES00116091T patent/ES2209728T3/es not_active Expired - Lifetime
- 2000-07-27 AT AT00116091T patent/ATE254614T1/de not_active IP Right Cessation
- 2000-07-27 DE DE60006618T patent/DE60006618T2/de not_active Expired - Fee Related
- 2000-08-01 MA MA26033A patent/MA26748A1/fr unknown
- 2000-08-01 CA CA002314798A patent/CA2314798A1/fr not_active Abandoned
- 2000-08-01 NZ NZ506096A patent/NZ506096A/xx unknown
- 2000-08-01 US US09/630,702 patent/US6218385B1/en not_active Expired - Fee Related
- 2000-08-02 ID IDP20000655A patent/ID26743A/id unknown
- 2000-08-02 PE PE2000000768A patent/PE20010467A1/es not_active Application Discontinuation
- 2000-08-02 HR HR20000520A patent/HRP20000520A2/hr not_active Application Discontinuation
- 2000-08-02 SG SG200004344A patent/SG93251A1/en unknown
- 2000-08-02 AU AU48979/00A patent/AU774485B2/en not_active Ceased
- 2000-08-02 ZA ZA200003927A patent/ZA200003927B/xx unknown
- 2000-08-03 IL IL13768800A patent/IL137688A0/xx unknown
- 2000-08-03 CO CO00058410A patent/CO5180625A1/es not_active Application Discontinuation
- 2000-08-04 JP JP2000236848A patent/JP3260350B2/ja not_active Expired - Fee Related
- 2000-08-04 AR ARP000104022A patent/AR025035A1/es not_active Application Discontinuation
- 2000-08-04 CN CNB001225235A patent/CN1146455C/zh not_active Expired - Fee Related
- 2000-08-04 HU HU0003112A patent/HUP0003112A3/hu unknown
- 2000-08-04 NO NO20003966A patent/NO20003966L/no not_active Application Discontinuation
- 2000-08-04 RU RU2000120522/04A patent/RU2240317C2/ru not_active IP Right Cessation
- 2000-08-04 UY UY26276A patent/UY26276A1/es not_active Application Discontinuation
- 2000-08-04 KR KR10-2000-0045324A patent/KR100390116B1/ko not_active Expired - Fee Related
- 2000-08-04 TR TR2000/02298A patent/TR200002298A3/tr unknown
- 2000-08-07 YU YU49700A patent/YU49700A/sh unknown
- 2000-08-07 BR BR0003375-8A patent/BR0003375A/pt not_active Application Discontinuation
- 2000-08-07 PL PL00341890A patent/PL341890A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26425A1 (fr) | Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26653A1 (fr) | Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| MA23831A1 (fr) | Derives de quinazoline, procede pour leur preparation et composition les contenant | |
| MA26468A1 (fr) | Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26472A1 (fr) | Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26680A1 (fr) | Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26505A1 (fr) | Derives de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26558A1 (fr) | Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2729951B1 (fr) | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant | |
| MA26424A1 (fr) | Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26614A1 (fr) | Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2783246B1 (fr) | Derives d'azetidine, leur preparation et les medicaments les contenant | |
| MA26479A1 (fr) | Derives de nicotinamide, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA25433A1 (fr) | Derives d'arylmethyl-carbonylamino-thiazole, leur procede de preparation et leur utilisation en tant qu'agents antitumoraux | |
| DZ2890A1 (fr) | 4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant. | |
| HUP0203294A3 (en) | Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
| FR2740136B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant | |
| MA26499A1 (fr) | Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant . | |
| MA24158A1 (fr) | Derives d'imidazole substitues, procede pour leur preparation et compositions les contenant | |
| MA26519A1 (fr) | Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26740A1 (fr) | Derives de 13-methyl-erythromycine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26624A1 (fr) | Derives de quinazolinamines nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2751334B1 (fr) | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |